King Pharmaceuticals KG Program Services — Commission and other acquisition expenses
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredPolicyAcquisitionCostAmortizationExpense.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's program services — commission and other acquisition expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is King Pharmaceuticals's program services — commission and other acquisition expenses?
- King Pharmaceuticals (KG) reported program services — commission and other acquisition expenses of $0 in Q1 2026.
- What does program services — commission and other acquisition expenses mean?
- Costs directly associated with acquiring new business, including commissions paid to agents or brokers and other policy acquisition costs. This metric helps evaluate the efficiency of the segment's distribution and sales strategy.